Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
11.84% $3.40
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 6.67 mill |
EPS: | -12.00 |
P/E: | -0.280 |
Earnings Date: | May 29, 2024 |
SharesOutstanding: | 1.962 mill |
Avg Daily Volume: | 0.587 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.280 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.05x |
Company: PE -0.280 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 3.09 - 3.71 ( +/- 9.24%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-08 | Runge Jeffrey W. | Buy | 470 | Options (right to buy) |
2023-11-08 | Albanna Rowena | Buy | 4 702 | Options (right to buy) |
2023-11-08 | Nelson Charles Athle | Buy | 470 | Options (right to buy) |
2023-11-08 | Albanna Amro A. | Buy | 9 404 | Options (right to buy) |
2023-11-08 | Pankovcin Corinne | Buy | 4 702 | Options (right to buy) |
INSIDER POWER |
---|
26.24 |
Last 84 transactions |
Buy: 1 934 500 | Sell: 1 185 103 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.40 (11.84% ) |
Volume | 0.188 mill |
Avg. Vol. | 0.587 mill |
% of Avg. Vol | 31.98 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:19 | buy | $3.86 | N/A | Active |
---|
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.